Anterior vs Infinx
Two Prior Authorization vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| Anterior | Infinx | |
|---|---|---|
| Pricing model | Enterprise contract (custom) · Payer enterprise deals only | Enterprise contract (custom) · Software plus services, quote-based |
| Speed to go live | Embedded team, deep payer integration | Standard EHR integration project |
| Automation model | AI copilot · Clinician-in-loop utilization review | Tech-enabled service · AI agents plus expert staff |
| Built for | Payers | Mid-size groups, Enterprise systems, Billing companies |
| Security posture | HIPAA | HITRUST, SOC 2 Type II, HIPAA |
| Company maturity | 3 yrs (est. 2023) | 14 yrs (est. 2012) |
| Financial backing | $64M · Series B | $186M reported · Growth (KKR minority stake 2024) |
| Named customers | 1 named | None public |
| Published results | Specific numbers public | No public numbers |
| Documented integrations | 1 listed | 5 listed |
| Third-party validation | KLAS / analyst cited | None found |
Bottom line
- Pick Anterior if you are a health plan that wants clinician-supervised AI to cut prior auth review time while keeping final decisions with your own staff.
- Pick Infinx if you want prior auth and revenue cycle work handled by a blend of AI and human specialists rather than buying software your staff must run.
Anterior
Clinician-led AI for health plan clinical reviews
- Founded
- 2023
- HQ
- New York, NY
- Stage
- Series B
- Raised
- $64M
What it does
- AI clinical reasoning against payer medical policies
- Prior authorization review with nurse-in-the-loop workflow
- Auto-approval of clean requests, flagging of edge cases
- Embedded clinicians who tune accuracy in production
- Audit trails for every determination
- Five-day average deployment into plan workflows
Where it's strong
- Clinical accuracy of 99.24% in live production was independently validated by KLAS Research.
- Founded and staffed by clinicians, which helps with medical director buy-in inside plans.
- Deploys into existing UM workflows in days rather than the multi-month integrations typical of payer software.
What buyers should weigh
- Sells only to payers, so provider organizations looking for a submission-side tool are not the buyer.
- Young company with a small number of named reference customers, so diligence on scale is warranted.
- State laws increasingly require licensed clinicians to make denial decisions, so buyers must define where AI output stops and human judgment starts.
Named customers
Geisinger Health Plan
Integrations
Infinx
AI plus specialists for prior auth and patient access
- Founded
- 2012
- HQ
- San Jose, CA
- Stage
- Growth (KKR minority stake 2024)
- Raised
- $186M reported
What it does
- AI prior authorization determination, submission, and status tracking
- Eligibility verification and benefits checks in one platform
- Patient pay estimates before service
- Certified specialists work exceptions automation cannot resolve
- AR recovery and denial management services
Where it's strong
- The AI-plus-human model delivers completed authorizations, not just software your staff still has to work.
- Deep roots in high-volume prior auth specialties like radiology, labs, and cardiology.
- Trusted by more than 900 provider organizations, with KKR and Norwest backing.
What buyers should weigh
- Part of the value is outsourced labor, so compare its per-transaction economics against pure software options.
- Named customer references are rare in public materials; case studies are anonymized.
- Broad service catalog means implementation scope needs careful definition up front.
Integrations
Compare against the rest of Prior Authorization
Deciding between these two?
First Pass tracks Prior Authorization every week: funding, launches, and what changed since this page was written.